Depression and Anxiety Disorders are the most common psychiatric disorders affecting a huge population across the globe. Depression; is related to a state Of emotion that further affects actions, thoughts and sometimes the sleeping pattern Of the concerned person. Depression is the most common type Of mental disorder affecting nearly 350 million patients Of varied scale age groups, whereas, anxiety is a reaction to stress. Extreme level Of anxiety result in anxiety disorders which include phobias, obsessive-compulsive disorder, panic disorder, post-traumatic based stress disorder.
The rising geriatric population, reduced side effects and greater efficacy Of new/innovative drugs along with the accelerating prevalence Of anxiety & depression disorders are contributing towards the growth Of this market. However, patent expiry for majority Of the drugs, dry pipeline for the novel drugs, mental disorders that are drug-resistant and growing numbers Of different generic drugs are analysed to impede the anxiety disorders and depression treatment market growth. The prospect Of innovations and developments in herbal remedies with an improved distribution network is Offers potential opportunities for the key participants.
Get Free Sample Report Of Anxiety disorders and depression treatment Market :http://www.marketresearchstore.com/report/world-anxiety-disorders-and-depression-treatment-market-68629#RequestSample
The global anxiety disorders and depression treatment market is segmented on the basis Of drug class, pipeline analysis and geography. The drug class segment is further categorized into SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors), TeCAs (Tetracyclic Antidepressants), TCAs (Tricyclic Antidepressants), MAOIs (Monoamine Oxidase inhibitors), Atypical Antipsychotics, Benzodiazepines, Anticonvulsants, Beta-Blockers and Others. On the basis Of pipeline analysis, the market is segmented into Brintellix (Vortioxetine – Lu AA21004), ALKS-5461 and Brexpiprazole (OPC-34712).
The progressive outcomes Of clinical trials for the related drugs and their anticipated commercialization in the forecast period will drive the growth for anxiolytic and antidepressant drugs in the future. Geographically, the global anxiety disorders and depression treatment market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America accounts for the largest market share, contributed by the U.S. due to the presence Of various branded formulations influencing the market dynamics extensively.
Have Any Query? Ask Our Expert @http://www.marketresearchstore.com/report/world-anxiety-disorders-and-depression-treatment-market-68629#InquiryForBuying
Key companies prOfiled in this market include Eli Lilly and Company, Forest Laboratories, Inc., AstraZeneca PLC, SanOfi-Aventis, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson and others. Recent developments, Clinical research, geographical expansion and enhanced distribution networks are the key strategies adopted by the key participants.
KEY MARKET SEGMENTS.
The global anxiety disorders and depression treatment Market is segmented into three major categories: drug class, pipeline analysis and geography.
MARKET BY DRUG CLASS
MARKET BY PIPELINE ANALYSIS
MARKET BY GEOGRAPHY
About Market Research Store
Market Research Store is a single destination for all the industry, company and country reports. We feature large repository Of latest industry reports, leading and niche company prOfiles, and market statistics released by reputed private publishers and public organizations. Market Research Store is the comprehensive collection Of market intelligence products and services available on air. We have market research reports from number Of leading publishers and update our collection daily to provide our clients with the instant online access to our database. With access to this database, our clients will be able to benefit from expert insights on global industries, products, and market trends.
3422 SW 15 Street, Suit #8138,
Deerfield Beach, Florida 33442,
GMT Tel: +49-322 210 92714
USA/Canada Toll Free No. 1-855-465-4651